All In Biotech

Drug Trial Radar · NCT04590326

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

612

Planned (sponsor's estimate)

Start

Dec 8, 2020

Primary completion

Nov 8, 2028

Study completion Nov 8, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main purposes of this study are to: * Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus * Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2. The study is looking at several other research questions, including: * Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab * How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab * How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood * To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
  • Endometrial Cancer

Interventions

  • REGN5668Drug

    Administer per the protocol

  • CemiplimabDrug

    Administer per the protocol

  • UbamatamabDrug

    Administer per the protocol

  • SarilumabDrug

    Administer per the protocol

  • Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]Drug

    Administer per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLT)Time frame: 42 days
  2. Incidence of DLTsTime frame: 21 days post combination administration
  3. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Through study completion, up to 5 years
  4. Incidence of Serious Adverse Events (SAEs)Time frame: Through study completion, up to 5 years
  5. Incidence of deathsTime frame: Through study completion, up to 5 years
  6. Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])Time frame: Through study completion, up to 5 years
  7. Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamabTime frame: Through study completion, up to 5 years
  8. Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)Time frame: Through study completion, up to 5 years

Locations

28 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • The City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • H. Lee Moffitt Cancer Center

    Tampa, Florida · Completed

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute Brookline Avenue

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio · Recruiting

  • Perelman School of Medicine at the University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Seattle Cancer Care Alliance at South Lake Union - G3630

    Seattle, Washington · Recruiting

  • Universitair Ziekenhuis Leuven

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • AC Camargo Cancer Center, Fundacao Antonio Prudente

    São Paulo, Brazil · Recruiting

  • Centro de Pesquisa em Oncologia PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Fundacao Pio XII - Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil · Recruiting

  • Unimed Sorocaba

    Sorocaba, São Paulo, Brazil · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Hopital Lyon Sud

    Pierre-Bénite, Auvergne-Rhône, France · Recruiting

  • Centre Georges Francois Leclerc

    Dijon, Bourgogne-Franche-Comté, France · Recruiting

  • Institut Bergonie

    Bordeaux, New Aquitaine, France · Recruiting

  • Centre Francois Baclesse (CFB)

    Caen, Normandy, France · Recruiting

  • Institut Catala dOncologia Girona

    Girona, Spain · Recruiting

  • Ciudad Universitaria

    Madrid, Spain · Recruiting

  • Hospital Universitario Fundacion Jimenez

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM

    Madrid, Spain · Recruiting

  • Hospital Clinico Universitario Santiago de Compostela

    Santiago de Compostela, A Coruna, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.